secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001725160-23-000154
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis Q2 cash $553M; azenosertib ORR 36.8% with RP2D set
-----------------------------------------------------------

- Cash, equivalents and marketable securities $553.0M as of June 30, 2023; runway into 2026.
- Azenosertib monotherapy ORR 36.8% in ovarian cancer/USC; RP2D set at 400 mg QD 5:2.
- Phase 1b azenosertib + paclitaxel ORR 50.0% (mPFS 7.4 mo); + carboplatin ORR 35.7% (mPFS 10.4 mo).
- Q2 R&D expense $42.7M, G&A $15.7M; one-time Zentera termination charge $45.6M.
- Closed $250M public offering (11.03M shares at $22.66) in June; appointed CSO Kimberly Freeman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000154/0001725160-23-000154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000154/zntl-20230809.htm
  HTML page:      https://secwatch.observer/filing/0001725160-23-000154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer